CVRx, Inc. (NASDAQ:CVRX) Stock Holdings Increased by Barclays PLC

Barclays PLC boosted its position in CVRx, Inc. (NASDAQ:CVRX) by 312.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,067 shares of the company’s stock after buying an additional 14,445 shares during the quarter. Barclays PLC owned approximately 0.08% of CVRx worth $169,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Parkman Healthcare Partners LLC boosted its position in shares of CVRx by 52.6% during the third quarter. Parkman Healthcare Partners LLC now owns 682,897 shares of the company’s stock worth $6,016,000 after buying an additional 235,277 shares during the period. Geode Capital Management LLC boosted its position in shares of CVRx by 2.2% during the third quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock worth $2,600,000 after buying an additional 6,443 shares during the period. State Street Corp boosted its position in shares of CVRx by 11.4% during the third quarter. State Street Corp now owns 264,733 shares of the company’s stock worth $2,332,000 after buying an additional 27,071 shares during the period. Squarepoint Ops LLC boosted its position in shares of CVRx by 26.3% during the second quarter. Squarepoint Ops LLC now owns 91,999 shares of the company’s stock worth $1,103,000 after buying an additional 19,165 shares during the period. Finally, PDT Partners LLC acquired a new position in shares of CVRx during the third quarter worth approximately $543,000. 75.27% of the stock is owned by institutional investors.

CVRx Price Performance

NASDAQ CVRX opened at $17.21 on Thursday. The stock has a market capitalization of $417.51 million, a P/E ratio of -6.37 and a beta of 1.26. CVRx, Inc. has a 1 year low of $6.40 and a 1 year high of $29.23. The business’s fifty day moving average is $14.27 and its two-hundred day moving average is $11.25. The company has a debt-to-equity ratio of 0.76, a quick ratio of 10.23 and a current ratio of 11.32.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.12). CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $13.28 million. During the same period in the prior year, the company posted ($0.43) EPS. On average, research analysts forecast that CVRx, Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Piper Sandler restated an “overweight” rating and issued a $16.00 target price (up from $13.00) on shares of CVRx in a research report on Wednesday, October 30th. Craig Hallum upped their target price on CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Canaccord Genuity Group upped their target price on CVRx from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Lake Street Capital upped their target price on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, William Blair upgraded CVRx from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, CVRx presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.